Sommario

• Editorial

  • ·Establishing a Trial Ready Cohort to Accelerate Alzheimer’s Clinical Trial Enrollment and Treatments

    Pagina :202-203

    E.A. Meyers, Maria C. Carrillo

    
  • ·Accelerating Preclinical Alzheimer’s Clinical Trials through a Trial-Ready Cohort with Diverse Representation

    Pagina :204-205

    A.K.W. Lee, S. Correia, Stephen P. Salloway

    
  • ·The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research

    Pagina :206-207

    A.P. Porsteinsson, E.D. Clark

    

• Special Article

  • ·The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview

    Pagina :208-212

    P.S. Aisen, R.A. Sperling, J. Cummings, M.C. Donohue, O. Langford, G.A. Jimenez-Maggiora, R.A. Rissman, M.S. Rafii, S. Walter, T. Clanton, R. Raman

    Riassunto Riassunto Mappa Mappa  
  • ·Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

    Pagina :213-218

    O. Langford, R. Raman, R.A. Sperling, J. Cummings, C.-K. Sun, G. Jimenez-Maggiora, P.S. Aisen, M.C. Donohue, TRC-PAD Investigators

    Riassunto Riassunto Mappa Mappa   
  • ·Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)

    Pagina :219-225

    S. Walter, T.B. Clanton, O.G. Langford, M.S. Rafii, E.J. Shaffer, J.D. Grill, G.A. Jimenez-Maggiora, R.A. Sperling, J.L. Cummings, P.S. Aisen, TRC-PAD Investigators

    Riassunto Riassunto Mappa Mappa  
  • ·TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology

    Pagina :226-233

    G.A. Jimenez-Maggiora, S. Bruschi, R. Raman, O. Langford, M. Donohue, M.S. Rafii, R.A. Sperling, J.L. Cummings, P.S. Aisen, TRC-PAD Investigators

    Riassunto Riassunto Mappa Mappa  
  • ·The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years

    Pagina :234-241

    S. Walter, O.G. Langford, T.B. Clanton, G.A. Jimenez-Maggiora, R. Raman, M.S. Rafii, E.J. Shaffer, R.A. Sperling, J.L. Cummings, P.S. Aisen, TRC-PAD Investigators

    Riassunto Riassunto Mappa Mappa  

• Original Research

  • ·The Alzheimer’s Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer’s-Focused Studies

    Pagina :242-250

    Jessica B. Langbaum, N. High, J. Nichols, C. Kettenhoven, E.M. Reiman, P.N. Tariot

    Riassunto Riassunto Mappa Mappa
  • ·Effectiveness of the Open Screening Programs in Recruiting Subjects to Prodromal and Mild Alzheimer’s Disease Clinical Trials

    Pagina :251-255

    Daniel Wójcik, K. Szczechowiak, M. Zboch, M. Pikala

    Riassunto Riassunto Mappa Mappa  
  • ·PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients

    Pagina :256-264

    H.-Y. Wang, Z. Pei, K.-C. Lee, E. Lopez-Brignoni, B. Nikolov, C.A. Crowley, M.R. Marsman, R. Barbier, N. Friedmann, Lindsay H. Burns

    Riassunto Riassunto Mappa Mappa  

• Reviews

  • ·The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E ε4, Lifestyle Factors, and the Aging Body and Brain

    Pagina :265-273

    Sara A. Galle, I.K. Geraedts, J.B. Deijen, M.V. Milders, M.L. Drent

    Riassunto Riassunto Mappa Mappa
  • ·A Framework for Developing Pharmacotherapy for Agitation in Alzheimer’s disease: Recommendations of the ISCTM Working Group

    Pagina :274-282

    Cedric O’Gorman, R. Khoury, A. Anderson, M. Carter, F. DiCesare, S. Dubé, L. Ereshefsky, G. Grossberg, N. Hefting, S. Khan, S. Lind, H. Moebius, T. Shiovitz, P. Rosenberg, ISCTM: International Society for CNS Clinical Trials and Methodology

    Mappa Mappa

• Brief Reports

  • ·Self-Administered Cognitive Testing by Older Adults At-Risk for Cognitive Decline

    Pagina :283-287

    Elena Tsoy, K.L. Possin, N. Thompson, K. Patel, S.K. Garrigues, I. Maravilla, S.J. Erlhoff, C.S. Ritchie

    Riassunto Riassunto Mappa Mappa  

• Viewpoint

  • ·The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs

    Pagina :288-290

    Jeffrey Cummings

    Mappa Mappa
  • ·A Missed Opportunity for Dementia Prevention? Current Challenges for Early Detection and Modern-Day Solutions

    Pagina :291-293

    Richard S. Isaacson, N. Saif

    
  • ·The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline

    Pagina :294-298

    Harald Hampel, Andrea Vergallo

    Riassunto Riassunto Mappa Mappa  

• Letter to the Editor

  • ·Letter to the editor referring to P.S. Aisen and R. Raman, Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer’s Disease, 2020

    Pagina :299-300

    Daniel Umbricht

    

• Response to the Letter to the Editor

  • ·Authors response to D. Umbricht letter to the editor referring Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer’s Disease, 2020

    Pagina :300

    P.S. Aisen, R. Raman

    

• Letter to the Editor

  • ·Toulouse Alzheimer’s Clinical Research Center Recovery after the COVID-19 Crisis: Telemedicine an Innovative Solution for Clinical Research during the Coronavirus Pandemic

    Pagina :301-304

    C. Takeda, S. Guyonnet, P.J. Ousset, M. Soto, B. Vellas

    Mappa Mappa